Welcome to LookChem.com Sign In|Join Free

CAS

  • or

50351-80-9

Post Buying Request

50351-80-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • SAGECHEM/7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine/SAGECHEM/Manufacturer in China

    Cas No: 50351-80-9

  • No Data

  • No Data

  • No Data

  • SAGECHEM LIMITED
  • Contact Supplier

50351-80-9 Usage

General Description

2,3,4,5-Tetrahydro-7-methoxy-1H-benzo[d]azepine is a chemical compound that belongs to the class of benzo[d]azepines. It is a heterocyclic compound with a seven-membered ring structure that contains nitrogen and oxygen atoms. 2,3,4,5-TETRAHYDRO-7-METHOXY-1H-BENZO[D]AZEPINE has a molecular formula of C11H15NO and a molecular weight of 177.24 g/mol. It is a colorless to light yellow liquid at room temperature and is soluble in organic solvents. 2,3,4,5-TETRAHYDRO-7-METHOXY-1H-BENZO[D]AZEPINE is used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical drugs, including antidepressants and antipsychotics. Its molecular structure and properties make it a useful intermediate in the production of biologically active compounds.

Check Digit Verification of cas no

The CAS Registry Mumber 50351-80-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,3,5 and 1 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 50351-80:
(7*5)+(6*0)+(5*3)+(4*5)+(3*1)+(2*8)+(1*0)=89
89 % 10 = 9
So 50351-80-9 is a valid CAS Registry Number.

50351-80-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine

1.2 Other means of identification

Product number -
Other names 1H-3-Benzazepine,2,3,4,5-tetrahydro-7-methoxy

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:50351-80-9 SDS

50351-80-9Relevant articles and documents

Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

Guo, Zheng,Zhang, Zixue,Zhang, Yi,Wang, Guan,Huang, Ziyi,Zhang, Qinwei,Li, Jianqi

, (2021/04/02)

Histone deacetylase 6 (HDAC6) has become a promising therapeutic target for central nervous system diseases due to its more complex protein structure and biological functions. However, low brain penetration of reported HDAC6 inhibitors limits its clinical application in neurological disorders. Therefore, the benzazepine, a brain-penetrant rigid fragment, was utilized to design a series of selective HDAC6 inhibitors to improve brain bioavailability. Various synthetic strategies were applied to assemble the tetrahydro-benzazepine ring, and 22 compounds were synthesized. Among them, compound 5 showed low nanomolar potency and strong isozyme selectivity for the inhibition of HDAC6 (IC50 = 1.8 nM, 141-fold selectivity over HDAC1) with efficient binding patterns like coordination with the zinc ion and π-π stacking effect. Western blot results showed it could efficiently transport into SH-SY5Y cells and selectively enhance the acetylation level of α-tubulin with a moderate effect on Histone H3. Notably, pharmacokinetic studies demonstrated that compound 5 (brain/plasma ratio of 2.30) had an excellent ability to penetrate the blood-brain barrier of C57 mice. In male rats with transient middle cerebral artery occlusion (MCAO), compound 5 significantly reduced the cerebral infarction from 21.22% to 11.47% and alleviated neurobehavioral deficits in post-ischemic treatment, which provided a strong rationale for pursuing HDAC6-based therapies for ischemic stroke.

Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity

Thum, Simone,Schepmann, Dirk,Ayet, Eva,Pujol, Marta,Nieto, Francisco R.,Ametamey, Simon M.,Wünsch, Bernhard

, p. 47 - 62 (2019/05/27)

The class of tetrahydro-1H-3-benzazepines was systematically modified in 1-, 3- and 7-position. In particular, a F-atom was introduced in β- or γ-position of the 4-phenylbutyl side chain in 3-position. Ligands with the F-atom in γ-position possess higher

Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists

Luckhurst, Christopher A.,Ratcliffe, Marianne,Stein, Linda,Furber, Mark,Botterell, Sara,Laughton, David,Tomlinson, Wendy,Weaver, Richard,Chohan, Kamaldeep,Walding, Andrew

scheme or table, p. 531 - 536 (2011/02/27)

We describe the discovery of small molecule benzazepine derivatives as agonists of human peroxisome proliferator-activated receptor δ (PPARδ) that displayed excellent selectivity over the PPARα and PPARγ subtypes. Compound 8 displayed good PK in the rat a

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50351-80-9